{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:08:34Z","timestamp":1791515314506,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2025.117272","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T07:30:16Z","timestamp":1736753416000},"page":"117272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Design, synthesis, and antitumor evaluation of triazolopyridine derivatives as novel inhibitors for BRD4"],"prefix":"10.1016","volume":"285","author":[{"given":"Jing-Ying","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-En","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Gen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-3693","authenticated-orcid":false,"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-3108","authenticated-orcid":false,"given":"Li-Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2025.117272_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"issue":"5942","key":"10.1016\/j.ejmech.2025.117272_bib2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117272_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117272_bib4","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","article-title":"Bromodomains: a new target class for drug development","volume":"18","author":"Cochran","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6735","key":"10.1016\/j.ejmech.2025.117272_bib5","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/20974","article-title":"Structure and ligand of a histone acetyltransferase bromodomain","volume":"399","author":"Dhalluin","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117272_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2023.102323","article-title":"Bromodomain inhibitors and therapeutic applications","volume":"75","author":"Gajjela","year":"2023","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117272_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108354","article-title":"BET proteins: biological functions and therapeutic interventions","volume":"243","author":"Guo","year":"2023","journal-title":"Pharmacology & Therapeutics"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117272_bib8","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrm.2016.143","article-title":"Functions of bromodomain-containing proteins and their roles in homeostasis and cancer","volume":"18","author":"Fujisawa","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7327","key":"10.1016\/j.ejmech.2025.117272_bib9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117272_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"20","key":"10.1016\/j.ejmech.2025.117272_bib11","article-title":"BET proteins as attractive targets for cancer therapeutics","volume":"22","author":"Sarnik","year":"2021"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117272_bib12","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2013-01-478420","article-title":"Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762","volume":"123","author":"Chaidos","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117272_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12342-2","article-title":"BRD4 regulates adiponectin gene induction by recruiting the P-TEFb complex to the transcribed region of the gene","volume":"7","author":"Sakurai","year":"2017","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117272_bib14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.chembiol.2014.05.009","article-title":"Selective chemical modulation of gene transcription favors oligodendrocyte lineage progression","volume":"21","author":"Gacias","year":"2014","journal-title":"Chem Biol"},{"issue":"7794","key":"10.1016\/j.ejmech.2025.117272_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41586-020-1930-8","article-title":"Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer","volume":"578","author":"Faivre","year":"2020","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117272_bib16","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1021\/acs.jmedchem.7b01666","article-title":"Discovery of tetrahydroquinoxalines as bromodomain and extra-terminal domain (BET) inhibitors with selectivity for the second bromodomain","volume":"61","author":"Law","year":"2018","journal-title":"J. Med. Chem."},{"issue":"6489","key":"10.1016\/j.ejmech.2025.117272_bib17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1126\/science.aaz8455","article-title":"Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation","volume":"368","author":"Gilan","year":"2020","journal-title":"Science"},{"issue":"49","key":"10.1016\/j.ejmech.2025.117272_bib18","doi-asserted-by":"crossref","first-page":"19754","DOI":"10.1073\/pnas.1310658110","article-title":"RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain","volume":"110","author":"Picaud","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117272_bib19","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1021\/acs.jmedchem.3c01837","article-title":"Structure-guided design and synthesis of pyridinone-based selective bromodomain and extra-terminal domain (BET)-First bromodomain (BD1) inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2025.117272_bib20","doi-asserted-by":"crossref","first-page":"21577","DOI":"10.1021\/acs.jmedchem.4c02516","article-title":"Discovery of the first BRD4 second bromodomain (BD2)-Selective inhibitors","volume":"67","author":"Li","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117272_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083190","article-title":"RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist","volume":"8","author":"Mclure","year":"2013","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.ejmech.2025.117272_bib22","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2020.3308","article-title":"Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial","volume":"323","author":"Ray","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.117272_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116052","article-title":"3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia","volume":"265","author":"Ali","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117272_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116592","article-title":"Design, synthesis and anticancer evaluation of 3-methyl-1H-indazole derivatives as novel selective bromodomain-containing protein 4 inhibitors","volume":"55","author":"Dong","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117272_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev-biochem-052610-095910","article-title":"RNA polymerase II elongation control","volume":"81","author":"Zhou","year":"2012","journal-title":"Annu. Rev. Biochem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:50:41Z","timestamp":1740379841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425000376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":25,"alternative-id":["S0223523425000376"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117272","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and antitumor evaluation of triazolopyridine derivatives as novel inhibitors for BRD4","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117272"}}